Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07791732 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)

Name: A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) — clinical trial record (NCT07791732)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorDaiichi Sankyo

Started2026-10-01

View on ClinicalTrials.gov ↗

Amendment history

2026-08-31

Study Status v1

Start date2026-09-01→2026-10-01

2026-08-24

Original filing

Daiichi Sankyo

69 trials monitored

See 8 trials at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as measured by progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR).

Trial Details

NCT Number	NCT07791732
Lead Sponsor	Daiichi Sankyo Collaborators: Merck Sharp & Dohme LLC
Conditions	Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
Enrollment	600 participants
Start Date	2026-10-01
Primary Completion	2029-07-01 (estimated)
Study Completion	2033-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-01